Le Lézard
Classified in: Business
Subject: ATY

Bronstein, Gewirtz & Grossman, LLC Alerts Consumers of Elmiron Dangers and Lawsuit


NEW YORK, July 4, 2020 /PRNewswire/ -- Attorney Advertising ? Did you take Elmiron for 6 months or longer for urinary pain from interstitial cystitis and experience maculopathy or any vision loss or eye damage?

Investigations have discovered that using Elmiron (pentosan polysulfate sodium) for urinary pain, can cause vision loss or blindness, a degenerative eye disorder, pigmentary maculopathy.

In 1985 Elmiron was approved as an "orphan drug", a special status for a drug to treat a rare disease or condition. Elmiron was an approved treatment for interstitial cystitis, a chronic condition that can cause severe bladder and pelvic pain, thought to affect as many as 1 million people (mainly women) in the United States.

Studies have found that roughly 25% of long-term Elmiron users may have developed a vision disorder. The disorder might have been diagnosed as macular degeneration or pattern dystrophy, and after further examiniation shown to be ocular damage, which is now linked to long-term use of Elmiron.

Patients who have taken Elmiron for an extended period of time may experience pigmentary retinal maculopathy, a degenerative visual disorder with symptoms including:

Anyone who took Elmiron for over 6 months and developed eye problems, vision loss or ocular damage may be eligible for compensation.

The lawsuit claims that Elmiron, manufactured by Janssen Pharmaceuticals, under Johnson & Johnson has known about the research linking Elmiron to vision loss since 2018, but has failed to warn consumers of the dangers.

Bronstein Gewirtz And Grossman is working tirelessly to alert consumers and to help consumers find out their rights. If you or a loved one has used Elmiron and have been diagnosed with vision problems, then you may be eligible for compensation. Know your rights! Reach out to Bronstein Gewirtz and Grossman LLC today. For more information, visit: www.bgandg.com/elmiron.    

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC


These press releases may also interest you

at 08:14
Trading resumes in: Company: Medicenna Therapeutics Corp. TSX Symbol: MDNA All Issues: Yes Resumption (ET): 8:30 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts...

at 08:09
Adyton Resources Corporation announces that it has filed its financial statements for the three and twelve months ended December 31, 2023 and accompanying Management Discussion and Analysis on its SEDAR profile at www.sedar.com. ...

at 08:07
The following issues have been halted by CIRO: Company: Medicenna Therapeutics Corp. TSX Symbol: MDNA All Issues: Yes Reason: Pending News Halt Time (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a...

at 08:05
Cutera, Inc. ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024....

at 08:05
The Beauty Health Company , home to flagship brand Hydrafacialtm, today announced it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. The Company will host an investor conference call at 4:30 p.m. Eastern...

at 08:05
Bragg Gaming Group Inc. ( NASDAQ: BRAG , TSX: BRAG ) (" Bragg " or the " Company"), a global B2B gaming technology and content provider, announced today that it will release its first quarter 2024 financial results prior to the opening of the...



News published on and distributed by: